ALPHA-BETA ACQUIRES TECHNOLOGYAlpha-beta Technology Inc. of Worcester, Mass., on Thursdaysaid it has acquired from Brigham and Women's Hospital inBoston exclusive rights to patented technology for developingcarbohydrate-based therapeutics for infectious diseases andimmune system disorders. The carbohydrates activate theimmune system by binding to proteins, called beta-glucanreceptors, on certain white blood cells.

GREENWICH SIGNS DEAL WITH KISSEI

Greenwich Pharmaceuticals Inc. said Thursday that it hasentered into a development agreement with KisseiPharmaceutical Co. Ltd. of Japan. Kissei will have an exclusiveoption to negotiate a license and development agreement forGreenwich's carbohydrate compound 80126 for Japan andSoutheast Asia, excluding China and Taiwan. In exchange, Kisseiwill pay Greenwich for a portion of the pre-clinicaldevelopment of 80126. The Fort Washington, Pa., company said80126 has demonstrated anti-inflammatory, anti-proliferativeand immunomodulatory properties.

APPLIED bioTECHNOLOGY AWARDED SBIR GRANT

Applied bioTechnology Inc. of Cambridge, Mass., has beenawarded a $50,000 Small Business Innovation Research grantfrom the National Institutes of Health. The grant will be used todevelop processes to produce non-infectious HIV-like particlesfor use in an AIDS vaccine.

VIMRx NAMES BOARD MEMBER, SCIENTIFIC DIRECTOR

VIMRx Pharmaceuticals Inc. of Stamford, Conn., said it hasnamed James M. McCormick to its board of directors andappointed Hershel Herzog scientific director. McCormick wasthe founder and past vice president of Adria Laboratories, andpreviously a vice president of Beecham Pharmaceuticals.Herzog was senior vice president for development operations atSchering-Plough Corp.

(c) 1997 American Health Consultants. All rights reserved.